Cargando…

Clinical Indications for Treatment with Multi-Kinase Inhibitors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer

SIMPLE SUMMARY: Differentiated thyroid cancer generally has an indolent, slow-growing nature. The disease gradually progresses in some of the patients and can ultimately develop into life-threatening conditions. Multi-kinase inhibitors including sorafenib and lenvatinib demonstrated prolonged progre...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukuda, Naoki, Takahashi, Shunji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126102/
https://www.ncbi.nlm.nih.gov/pubmed/34068664
http://dx.doi.org/10.3390/cancers13092279
_version_ 1783693701952831488
author Fukuda, Naoki
Takahashi, Shunji
author_facet Fukuda, Naoki
Takahashi, Shunji
author_sort Fukuda, Naoki
collection PubMed
description SIMPLE SUMMARY: Differentiated thyroid cancer generally has an indolent, slow-growing nature. The disease gradually progresses in some of the patients and can ultimately develop into life-threatening conditions. Multi-kinase inhibitors including sorafenib and lenvatinib demonstrated prolonged progression-free survival compared with the placebo in pivotal phase 3 trials for patients with radioactive iodine-refractory, progressive disease. However, the overall survival benefit was not confirmed because of the cross-over design of the trials. Therefore, the initiation of treatment with multi-kinase inhibitors should be carefully considered according to the patients and their disease conditions. In this review, we comprehensively describe the currently reported factors that can be potential indications, and further attempt to provide a simplified list of indications for the initiation of multi-kinase inhibitor treatment in patients with radioactive iodine-refractory differentiated thyroid cancer. ABSTRACT: Differentiated thyroid cancer is usually a slow-growing disease, even if the patients develop distant metastasis. For recurrent or metastatic disease, radioactive iodine therapy is a standard treatment. However, the disease gradually progresses in some of the patients and can ultimately develop into life-threatening conditions. For patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RR-DTC), multi-kinase inhibitors (MKIs) including sorafenib and lenvatinib prolonged progression-free survival compared with placebo in pivotal randomized phase 3 trials, although the benefit in overall survival has not been clearly confirmed, possibly because the patients who received placebo were permitted to cross-over to lenvatinib upon disease progression. Moreover, the adverse events related to MKIs were not negligible. Therefore, the optimal timing of MKI initiation has long been controversial, and physicians should consider various patient and disease factors. Herein, we comprehensively review the clinical factors that can be helpful in determining the initiation of MKIs for patients with RR-DTC.
format Online
Article
Text
id pubmed-8126102
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81261022021-05-17 Clinical Indications for Treatment with Multi-Kinase Inhibitors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Fukuda, Naoki Takahashi, Shunji Cancers (Basel) Review SIMPLE SUMMARY: Differentiated thyroid cancer generally has an indolent, slow-growing nature. The disease gradually progresses in some of the patients and can ultimately develop into life-threatening conditions. Multi-kinase inhibitors including sorafenib and lenvatinib demonstrated prolonged progression-free survival compared with the placebo in pivotal phase 3 trials for patients with radioactive iodine-refractory, progressive disease. However, the overall survival benefit was not confirmed because of the cross-over design of the trials. Therefore, the initiation of treatment with multi-kinase inhibitors should be carefully considered according to the patients and their disease conditions. In this review, we comprehensively describe the currently reported factors that can be potential indications, and further attempt to provide a simplified list of indications for the initiation of multi-kinase inhibitor treatment in patients with radioactive iodine-refractory differentiated thyroid cancer. ABSTRACT: Differentiated thyroid cancer is usually a slow-growing disease, even if the patients develop distant metastasis. For recurrent or metastatic disease, radioactive iodine therapy is a standard treatment. However, the disease gradually progresses in some of the patients and can ultimately develop into life-threatening conditions. For patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RR-DTC), multi-kinase inhibitors (MKIs) including sorafenib and lenvatinib prolonged progression-free survival compared with placebo in pivotal randomized phase 3 trials, although the benefit in overall survival has not been clearly confirmed, possibly because the patients who received placebo were permitted to cross-over to lenvatinib upon disease progression. Moreover, the adverse events related to MKIs were not negligible. Therefore, the optimal timing of MKI initiation has long been controversial, and physicians should consider various patient and disease factors. Herein, we comprehensively review the clinical factors that can be helpful in determining the initiation of MKIs for patients with RR-DTC. MDPI 2021-05-10 /pmc/articles/PMC8126102/ /pubmed/34068664 http://dx.doi.org/10.3390/cancers13092279 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Fukuda, Naoki
Takahashi, Shunji
Clinical Indications for Treatment with Multi-Kinase Inhibitors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer
title Clinical Indications for Treatment with Multi-Kinase Inhibitors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer
title_full Clinical Indications for Treatment with Multi-Kinase Inhibitors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer
title_fullStr Clinical Indications for Treatment with Multi-Kinase Inhibitors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer
title_full_unstemmed Clinical Indications for Treatment with Multi-Kinase Inhibitors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer
title_short Clinical Indications for Treatment with Multi-Kinase Inhibitors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer
title_sort clinical indications for treatment with multi-kinase inhibitors in patients with radioiodine-refractory differentiated thyroid cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126102/
https://www.ncbi.nlm.nih.gov/pubmed/34068664
http://dx.doi.org/10.3390/cancers13092279
work_keys_str_mv AT fukudanaoki clinicalindicationsfortreatmentwithmultikinaseinhibitorsinpatientswithradioiodinerefractorydifferentiatedthyroidcancer
AT takahashishunji clinicalindicationsfortreatmentwithmultikinaseinhibitorsinpatientswithradioiodinerefractorydifferentiatedthyroidcancer